FDA Drafts Guidance on Waiver of Bioavailability and Bioequivalence Studies for Certain Medications

Summary

The FDA is releasing a draft guidance that outlines recommendations for sponsors of new drug applications to waive in vivo bioavailability and bioequivalence studies for certain medications, allowing for faster development and approval of immediate-release solid oral dosage forms.